Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Novo Nordisk is targeting more than $23 billion in pipeline sales by 2035, but investors remain cautious as competition, pricing pressure and future patent expirations threaten the company’s long-term growth.

Novo Nordisk has outlined an ambitious plan to launch more than five blockbuster medicines by 2030, but investors remain concerned about the company’s future beyond Ozempic and Wegovy.

The Danish pharmaceutical group is targeting more than 150 billion Danish crowns, approximately $23 billion, in annual pipeline sales by 2035. It also wants to reach more than 60 million patients globally by 2030 and expand its manufacturing capacity for oral obesity treatments.

Despite those targets, Novo shares fell as much as 9% as investors questioned its pricing power, acquisition strategy and ability to develop successors to its most valuable medicines.

The reaction reflects the pressure building around Novo’s pipeline.

Ozempic and Wegovy transformed the company into a global leader in obesity and diabetes care. However, both contain semaglutide, which is expected to begin losing patent protection in major markets during the early 2030s.

Novo now has several years to build its next generation of treatments.

The company plans to begin with CagriSema, a combination obesity medicine targeted for launch in early 2027. Standalone cagrilintide and a higher-dose version of CagriSema could follow in 2028, with further treatments expected later.

Oral medicines will also play a central role. Novo aims to have at least five oral treatments in clinical trials by the end of 2026, potentially allowing it to reach patients who prefer tablets over weekly injections.

Demand already appears strong. The company said oral Wegovy has reached seven million US prescriptions, with approximately 90% coming through direct cash-payment channels.

However, expanding access could place additional pressure on pricing. Reaching tens of millions of patients may require lower-cost treatments, meaning higher prescription volumes will not automatically produce the same level of profit growth.

Competition is another concern. Eli Lilly continues to expand its own obesity portfolio, increasing the pressure on Novo to deliver treatments that are more effective, convenient or affordable.

For investors, Novo’s challenge is no longer proving that obesity medicines can become blockbuster products. It must show that it can defend its position while building a pipeline capable of replacing semaglutide as patent protection weakens.

The company has presented an ambitious route forward. The sharp decline in its shares suggests investors now want stronger evidence that it can deliver.